Switch to:
Also traded in: Australia, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.65
RMD's Cash to Debt is ranked lower than
52% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. RMD: 1.65 )
Ranked among companies with meaningful Cash to Debt only.
RMD' s Cash to Debt Range Over the Past 10 Years
Min: 0.33  Med: 2.39 Max: No Debt
Current: 1.65
Equity to Asset 0.69
RMD's Equity to Asset is ranked higher than
63% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.62 vs. RMD: 0.69 )
Ranked among companies with meaningful Equity to Asset only.
RMD' s Equity to Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.75 Max: 0.86
Current: 0.69
0.34
0.86
Interest Coverage 19.03
RMD's Interest Coverage is ranked higher than
51% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.08 vs. RMD: 19.03 )
Ranked among companies with meaningful Interest Coverage only.
RMD' s Interest Coverage Range Over the Past 10 Years
Min: 55.55  Med: 5075.42 Max: 9999.99
Current: 19.03
55.55
9999.99
F-Score: 7
Z-Score: 10.26
M-Score: -2.34
WACC vs ROIC
5.93%
27.34%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 23.12
RMD's Operating margin (%) is ranked higher than
89% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. RMD: 23.12 )
Ranked among companies with meaningful Operating margin (%) only.
RMD' s Operating margin (%) Range Over the Past 10 Years
Min: 12.59  Med: 21.57 Max: 26.05
Current: 23.12
12.59
26.05
Net-margin (%) 19.56
RMD's Net-margin (%) is ranked higher than
92% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.00 vs. RMD: 19.56 )
Ranked among companies with meaningful Net-margin (%) only.
RMD' s Net-margin (%) Range Over the Past 10 Years
Min: 9.26  Med: 17.83 Max: 22.2
Current: 19.56
9.26
22.2
ROE (%) 22.28
RMD's ROE (%) is ranked higher than
90% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.62 vs. RMD: 22.28 )
Ranked among companies with meaningful ROE (%) only.
RMD' s ROE (%) Range Over the Past 10 Years
Min: 7.94  Med: 15.16 Max: 21.1
Current: 22.28
7.94
21.1
ROA (%) 15.21
RMD's ROA (%) is ranked higher than
92% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.92 vs. RMD: 15.21 )
Ranked among companies with meaningful ROA (%) only.
RMD' s ROA (%) Range Over the Past 10 Years
Min: 5.87  Med: 12.13 Max: 15.53
Current: 15.21
5.87
15.53
ROC (Joel Greenblatt) (%) 54.36
RMD's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.41 vs. RMD: 54.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RMD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 19.19  Med: 39.05 Max: 57.32
Current: 54.36
19.19
57.32
Revenue Growth (3Y)(%) 8.70
RMD's Revenue Growth (3Y)(%) is ranked higher than
68% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. RMD: 8.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RMD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 8.7  Med: 23.80 Max: 32.3
Current: 8.7
8.7
32.3
EBITDA Growth (3Y)(%) 8.40
RMD's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.30 vs. RMD: 8.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RMD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 6  Med: 21.30 Max: 76.3
Current: 8.4
6
76.3
EPS Growth (3Y)(%) 13.00
RMD's EPS Growth (3Y)(%) is ranked higher than
68% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.60 vs. RMD: 13.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RMD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 20.30 Max: 66.7
Current: 13
0
66.7
» RMD's 10-Y Financials

Financials (Next Earnings Date: 2016-07-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

RMD Guru Trades in Q2 2015

Paul Tudor Jones 6,500 sh (New)
Ray Dalio 5,988 sh (New)
John Hussman 75,000 sh (+2042.86%)
Jim Simons Sold Out
Jeremy Grantham 109,903 sh (-0.72%)
» More
Q3 2015

RMD Guru Trades in Q3 2015

Ken Fisher 19,025 sh (New)
Jim Simons 1,361,000 sh (New)
Joel Greenblatt 4,210 sh (New)
Ray Dalio 13,788 sh (+130.26%)
Paul Tudor Jones Sold Out
John Hussman 50,000 sh (-33.33%)
Jeremy Grantham 72,503 sh (-34.03%)
» More
Q4 2015

RMD Guru Trades in Q4 2015

George Soros 12,800 sh (New)
Paul Tudor Jones 9,100 sh (New)
Ken Fisher 19,025 sh (unchged)
John Hussman 50,000 sh (unchged)
Ray Dalio Sold Out
Joel Greenblatt Sold Out
Jim Simons 1,266,100 sh (-6.97%)
Jeremy Grantham 37,303 sh (-48.55%)
» More
Q1 2016

RMD Guru Trades in Q1 2016

Steven Cohen 332,200 sh (New)
Joel Greenblatt 112,449 sh (New)
Ray Dalio 49,576 sh (New)
Paul Tudor Jones 17,831 sh (+95.95%)
Ken Fisher 20,950 sh (+10.12%)
Jim Simons 1,283,100 sh (+1.34%)
Jeremy Grantham Sold Out
George Soros Sold Out
John Hussman 2,300 sh (-95.40%)
» More
» Details

Insider Trades

Latest Guru Trades with RMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NYSE:COO, NAS:HOLX, NYSE:MTD, NYSE:WAT, NAS:SIRO, OTCPK:SAUHY, NYSE:STE, OTCPK:OCPNY, NYSE:WST, OTCPK:GNGBY, NAS:XRAY, NYSE:HRC, NYSE:CMN, OTCPK:CLPBY, OTCPK:TRUMY, OTCPK:ANSLF, OTCPK:AMFPF, NAS:PODD, NAS:ICUI, NYSE:BCR » details
Traded in other countries:RMD.Australia, RME.Germany, RSMDF.USA,
ResMed Inc is a developer, manufacturer and distributor of medical products for treating, diagnosing and managing sleep-disordered breathing and other respiratory disorders.

ResMed Inc a Delaware corporation was formed in March, 1994. The Company is engaged in the development, manufacturing, distribution and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing, or SDB. SDB includes obstructive sleep apnea, or OSA, and other respiratory disorders that occur during sleep. SDB includes obstructive sleep apnea, or OSA, and other respiratory disorders that occur during sleep. The Company markets its products in more than 100 countries to sleep clinics, home healthcare dealers and third-party payors. It also markets the products directly to sleep clinics. The Company's portfolio of products include airflow generators, diagnostic products, mask systems, headgear and other accessories. The Company produces CPAP, VPAP and AutoSet systems for the titration and treatment of SDB. The flow generator systems deliver positive airway pressure through a patient interface, either a small nasal mask, nasal pillows system, or full-face mask. The Company's competitors include Philips BV, DeVilbiss Healthcare, Fisher & Paykel Healthcare Corporation Limited, Apex Medical Corporation, BMC Medical Co. Ltd. and regional manufacturers. The Company's products are subject to extensive regulation particularly as to safety, efficacy and adherence to FDA Quality System Regulation, and related manufacturing standards. Medical device products are subject to rigorous FDA and other governmental agency regulations in the United States and similar regulations of foreign agencies abroad.

Ratios

vs
industry
vs
history
P/E(ttm) 26.84
RMD's P/E(ttm) is ranked higher than
55% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.89 vs. RMD: 26.84 )
Ranked among companies with meaningful P/E(ttm) only.
RMD' s P/E(ttm) Range Over the Past 10 Years
Min: 16.93  Med: 23.63 Max: 66.38
Current: 26.84
16.93
66.38
Forward P/E 21.55
RMD's Forward P/E is ranked higher than
59% of the 41 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.32 vs. RMD: 21.55 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 26.84
RMD's PE(NRI) is ranked higher than
55% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.89 vs. RMD: 26.84 )
Ranked among companies with meaningful PE(NRI) only.
RMD' s PE(NRI) Range Over the Past 10 Years
Min: 16.93  Med: 23.56 Max: 64.76
Current: 26.84
16.93
64.76
Price/Owner Earnings (ttm) 22.87
RMD's Price/Owner Earnings (ttm) is ranked higher than
64% of the 76 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.98 vs. RMD: 22.87 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
RMD' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 12.88  Med: 24.26 Max: 249.29
Current: 22.87
12.88
249.29
P/B 5.52
RMD's P/B is ranked lower than
74% of the 207 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. RMD: 5.52 )
Ranked among companies with meaningful P/B only.
RMD' s P/B Range Over the Past 10 Years
Min: 2.29  Med: 3.65 Max: 6.86
Current: 5.52
2.29
6.86
P/S 5.29
RMD's P/S is ranked lower than
71% of the 212 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.03 vs. RMD: 5.29 )
Ranked among companies with meaningful P/S only.
RMD' s P/S Range Over the Past 10 Years
Min: 2.77  Med: 4.50 Max: 6.91
Current: 5.29
2.77
6.91
PFCF 21.84
RMD's PFCF is ranked higher than
64% of the 84 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.29 vs. RMD: 21.84 )
Ranked among companies with meaningful PFCF only.
RMD' s PFCF Range Over the Past 10 Years
Min: 13.35  Med: 25.16 Max: 304.88
Current: 21.84
13.35
304.88
POCF 18.92
RMD's POCF is ranked lower than
59% of the 103 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.88 vs. RMD: 18.92 )
Ranked among companies with meaningful POCF only.
RMD' s POCF Range Over the Past 10 Years
Min: 10.7  Med: 19.27 Max: 50.46
Current: 18.92
10.7
50.46
EV-to-EBIT 20.21
RMD's EV-to-EBIT is ranked higher than
55% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.84 vs. RMD: 20.21 )
Ranked among companies with meaningful EV-to-EBIT only.
RMD' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.8  Med: 17.40 Max: 48.6
Current: 20.21
10.8
48.6
EV-to-EBITDA 17.18
RMD's EV-to-EBITDA is ranked higher than
51% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.39 vs. RMD: 17.18 )
Ranked among companies with meaningful EV-to-EBITDA only.
RMD' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.5  Med: 14.20 Max: 29.5
Current: 17.18
8.5
29.5
PEG 2.02
RMD's PEG is ranked higher than
62% of the 61 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.59 vs. RMD: 2.02 )
Ranked among companies with meaningful PEG only.
RMD' s PEG Range Over the Past 10 Years
Min: 0.7  Med: 1.46 Max: 5.05
Current: 2.02
0.7
5.05
Shiller P/E 40.30
RMD's Shiller P/E is ranked higher than
50% of the 48 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 40.46 vs. RMD: 40.30 )
Ranked among companies with meaningful Shiller P/E only.
RMD' s Shiller P/E Range Over the Past 10 Years
Min: 30.9  Med: 44.34 Max: 84.78
Current: 40.3
30.9
84.78
Current Ratio 4.89
RMD's Current Ratio is ranked higher than
81% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.51 vs. RMD: 4.89 )
Ranked among companies with meaningful Current Ratio only.
RMD' s Current Ratio Range Over the Past 10 Years
Min: 0.87  Med: 4.23 Max: 6.44
Current: 4.89
0.87
6.44
Quick Ratio 4.07
RMD's Quick Ratio is ranked higher than
81% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. RMD: 4.07 )
Ranked among companies with meaningful Quick Ratio only.
RMD' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 3.25 Max: 5.71
Current: 4.07
0.61
5.71
Days Inventory 117.11
RMD's Days Inventory is ranked higher than
57% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.38 vs. RMD: 117.11 )
Ranked among companies with meaningful Days Inventory only.
RMD' s Days Inventory Range Over the Past 10 Years
Min: 100.51  Med: 141.93 Max: 168.51
Current: 117.11
100.51
168.51
Days Sales Outstanding 73.73
RMD's Days Sales Outstanding is ranked lower than
65% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.94 vs. RMD: 73.73 )
Ranked among companies with meaningful Days Sales Outstanding only.
RMD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 75.52  Med: 81.81 Max: 85.51
Current: 73.73
75.52
85.51
Days Payable 37.85
RMD's Days Payable is ranked lower than
64% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.12 vs. RMD: 37.85 )
Ranked among companies with meaningful Days Payable only.
RMD' s Days Payable Range Over the Past 10 Years
Min: 36.65  Med: 48.06 Max: 71.45
Current: 37.85
36.65
71.45

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.81
RMD's Dividend Yield is ranked higher than
65% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.24 vs. RMD: 1.81 )
Ranked among companies with meaningful Dividend Yield only.
RMD' s Dividend Yield Range Over the Past 10 Years
Min: 0.41  Med: 1.85 Max: 2.26
Current: 1.81
0.41
2.26
Dividend Payout 0.48
RMD's Dividend Payout is ranked higher than
94% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.32 vs. RMD: 0.48 )
Ranked among companies with meaningful Dividend Payout only.
RMD' s Dividend Payout Range Over the Past 10 Years
Min: 0.29  Med: 0.44 Max: 0.53
Current: 0.48
0.29
0.53
Forward Dividend Yield 1.84
RMD's Forward Dividend Yield is ranked higher than
63% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.44 vs. RMD: 1.84 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.81
RMD's Yield on cost (5-Year) is ranked lower than
52% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.61 vs. RMD: 1.81 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
RMD' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.41  Med: 1.85 Max: 2.26
Current: 1.81
0.41
2.26
3-Year Average Share Buyback Ratio 0.40
RMD's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. RMD: 0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RMD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.6  Med: -2.00 Max: 2.6
Current: 0.4
-4.6
2.6

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 14.67
RMD's Price/Net Current Asset Value is ranked lower than
73% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.62 vs. RMD: 14.67 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RMD' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.73  Med: 9.61 Max: 1340
Current: 14.67
3.73
1340
Price/Tangible Book 8.38
RMD's Price/Tangible Book is ranked lower than
78% of the 176 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.52 vs. RMD: 8.38 )
Ranked among companies with meaningful Price/Tangible Book only.
RMD' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.97  Med: 5.96 Max: 35.03
Current: 8.38
2.97
35.03
Price/Projected FCF 1.67
RMD's Price/Projected FCF is ranked higher than
60% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.91 vs. RMD: 1.67 )
Ranked among companies with meaningful Price/Projected FCF only.
RMD' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.35  Med: 3.27 Max: 59.76
Current: 1.67
1.35
59.76
Price/DCF (Earnings Based) 0.94
RMD's Price/DCF (Earnings Based) is ranked higher than
83% of the 18 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.91 vs. RMD: 0.94 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.17
RMD's Price/Median PS Value is ranked lower than
51% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. RMD: 1.17 )
Ranked among companies with meaningful Price/Median PS Value only.
RMD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.58  Med: 1.04 Max: 2.58
Current: 1.17
0.58
2.58
Price/Peter Lynch Fair Value 2.49
RMD's Price/Peter Lynch Fair Value is ranked higher than
52% of the 42 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. RMD: 2.49 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
RMD' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.73  Med: 1.42 Max: 6.75
Current: 2.49
0.73
6.75
Price/Graham Number 3.16
RMD's Price/Graham Number is ranked lower than
63% of the 92 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.42 vs. RMD: 3.16 )
Ranked among companies with meaningful Price/Graham Number only.
RMD' s Price/Graham Number Range Over the Past 10 Years
Min: 1.49  Med: 2.74 Max: 15.87
Current: 3.16
1.49
15.87
Earnings Yield (Greenblatt) (%) 4.87
RMD's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.33 vs. RMD: 4.87 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RMD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.1  Med: 5.70 Max: 9.3
Current: 4.87
2.1
9.3
Forward Rate of Return (Yacktman) (%) 14.21
RMD's Forward Rate of Return (Yacktman) (%) is ranked higher than
72% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.73 vs. RMD: 14.21 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
RMD' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 13  Med: 20.30 Max: 31.1
Current: 14.21
13
31.1

More Statistics

Revenue (TTM) (Mil) $1,773
EPS (TTM) $ 2.45
Beta0.60
Short Percentage of Float8.32%
52-Week Range $48.99 - 66.47
Shares Outstanding (Mil)140.41

Analyst Estimate

Jun16 Jun17
Revenue (Mil $) 1,822 2,042
EPS ($) 2.50 3.01
EPS w/o NRI ($) 2.50 3.01
EPS Growth Rate
(3Y to 5Y Estimate)
10.67%
Dividends Per Share ($) 1.14 1.34
» More Articles for NYSE:RMD

Headlines

Articles On GuruFocus.com
Hologic Produces the First FDA-Approved 3D Mammography Platform Nov 26 2014 
These 7 Growth Stocks Have Potential To Make You Rich Sep 14 2014 
Buy ResMed and Sleep Tight (Like Jim Simons) Feb 02 2014 
3 Cheap Health Care Dividend Stocks with Huge Potential to Grow Dividends Oct 02 2013 
Meeting the Herd Mar 25 2013 
The Best Yielding Ex-Dividend Stocks on February 14, 2013 Feb 13 2013 
Weekly CEO Sells Highlight: ResMed Inc., Chuy’s Holdings Inc., Electronics for Imaging Inc., Coher Feb 04 2013 
ResMed - Growing Business with Consistent Cash Flow Generation at Lowest 10-Year Valuation Jan 24 2012 
Weekly CFO Sells Highlight: RMD, CATM, HXL, BCR, AMRC Jul 24 2011 
You'll Sleep Better with ResMed in Your Portfolio Jun 26 2011 

More From Other Websites
ResMed annual profit flat at $US352m Jul 28 2016
ResMed meets 4Q profit forecasts Jul 28 2016
ResMed meets 4Q profit forecasts Jul 28 2016
4:33 pm ResMed misses by $0.01, reports revs in-line; increases quarterly dividend 10% to... Jul 28 2016
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2016 Jul 28 2016
RESMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Jul 28 2016
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2016 Jul 28 2016
Q4 2016 ResMed Inc Earnings Release - After Market Close Jul 28 2016
Look at Medical Product Earnings on Jul 28: BSX, RMD & More Jul 27 2016
ETF’s with exposure to ResMed, Inc. : July 21, 2016 Jul 21 2016
ResMed (RMD) Q4 Earnings: Disappointment in the Cards? Jul 20 2016
ResMed to Announce Fourth Quarter Fiscal Year 2016 Results Jul 07 2016
ResMed to Announce Fourth Quarter Fiscal Year 2016 Results Jul 07 2016
ResMed Awarded Group Purchasing Contract with Premier Jun 28 2016
ResMed Awarded Group Purchasing Contract with Premier Jun 28 2016
ResMed : All Eyes on Brightree Buyout , Growth Plans on Track Jun 27 2016
ResMed downgraded by Needham Jun 27 2016
Stocks Mixed After Yellen Speech; Microsoft, Apple Rise Jun 21 2016
ResMed, Inc. – Value Analysis (NYSE:RMD) : June 21, 2016 Jun 21 2016
ResMed Statement on Brightree Executive Appointments Jun 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)